{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:06:10Z","timestamp":1793297170710,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Rezafungin is a novel echinocandin with a unique structural configuration enabling weekly IV dosing. We report on early use of rezafungin in our outpatient parenteral antibiotic therapy (OPAT) service, reviewing indications, treatment regimens, outcomes and adverse events in adult patients receiving rezafungin at a tertiary infectious disease centre. We also review published cases of rezafungin use, licensing trials, spectrum and pharmacokinetics\/pharmacodynamics and how that might relate to its propensity to generate resistance (in comparison with daily echinocandins).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All adult patients who received rezafungin therapy via the OPAT service in 2024\u201325 were included. Patient demographics, infections, treatment regimens and outcomes were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six patients (age range 30\u201384\u2005years) received rezafungin therapy between July 2024 and February 2025. Indications included invasive and mucocutaneous candidiasis, predominantly caused by azole-resistant Candida species. We also report the first case of using rezafungin in combination with voriconazole to treat azole-refractory pulmonary aspergillosis. Rezafungin courses were a median length of 4 doses (range: 2\u20135) and were generally well tolerated with no laboratory adverse events. Reasons for choosing rezafungin over daily echinocandins were patient preference\/convenience (n\u200a=\u200a5), concern regarding azole resistance (n\u200a=\u200a4) and facilitation of earlier discharge (n\u200a=\u200a2). One hundred and fifty-seven days with an IV catheter were saved through once-weekly dosing. Outcomes were positive, with all patients showing mycological clearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early use of rezafungin at our centre and in the international literature suggests it is a well-tolerated, convenient and useful addition to the antifungal armamentarium, particularly in the outpatient setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf143","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:52:29Z","timestamp":1746042749000},"page":"1885-1892","source":"Crossref","is-referenced-by-count":10,"title":["Early use of the novel antifungal rezafungin: a case series and literature review"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4222-4358","authenticated-orcid":false,"given":"H C","family":"Davidson","sequence":"first","affiliation":[{"name":"Institute of Infection and Immunity, St George\u2019s School of Health and Medical Sciences, City St George\u2019s University of London , London SW17 0RE ,","place":["UK"]},{"name":"ECMM Excellence Center, St George\u2019s University Hospitals NHS Foundation Trust , London SW17 0QT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Yau","sequence":"additional","affiliation":[{"name":"Pharmacy, St George\u2019s University Hospitals NHS Foundation Trust , London SW17 0QT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Dunstan","sequence":"additional","affiliation":[{"name":"Department of Infection, OPAT Team, St George\u2019s University Hospitals NHS Foundation Trust , London SW17 0QT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Houston","sequence":"additional","affiliation":[{"name":"ECMM Excellence Center, St George\u2019s University Hospitals NHS Foundation Trust , London SW17 0QT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Basarab","sequence":"additional","affiliation":[{"name":"ECMM Excellence Center, St George\u2019s University Hospitals NHS Foundation Trust , London SW17 0QT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2676-838X","authenticated-orcid":false,"given":"T","family":"Bicanic","sequence":"additional","affiliation":[{"name":"Institute of Infection and Immunity, St George\u2019s School of Health and Medical Sciences, City St George\u2019s University of London , London SW17 0RE ,","place":["UK"]},{"name":"ECMM Excellence Center, St George\u2019s University Hospitals NHS Foundation Trust , London SW17 0QT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"2025070104562519300_dkaf143-B1","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s00134-020-06240-x","article-title":"Invasive candidiasis in critical care: challenges and future directions","volume":"46","author":"Logan","year":"2020","journal-title":"Intensive Care Med"},{"key":"2025070104562519300_dkaf143-B2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/bies.20441","article-title":"The structure and synthesis of the fungal cell wall","volume":"28","author":"Bowman","year":"2006","journal-title":"Bioessays"},{"key":"2025070104562519300_dkaf143-B3","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1128\/AAC.43.4.830","article-title":"LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability","volume":"43","author":"Green","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B4","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025070104562519300_dkaf143-B5","doi-asserted-by":"publisher","first-page":"myad131","DOI":"10.1093\/mmy\/myad131","article-title":"Candida parapsilosis: a systematic review to inform the World Health Organization fungal priority pathogens list","volume":"62","author":"Asogan","year":"2024","journal-title":"Med Mycol"},{"key":"2025070104562519300_dkaf143-B6","doi-asserted-by":"publisher","first-page":"myae045","DOI":"10.1093\/mmy\/myae045","article-title":"Candida albicans\u2014a systematic review to inform the World Health Organization fungal priority pathogens list","volume":"62","author":"Parambath","year":"2024","journal-title":"Med Mycol"},{"key":"2025070104562519300_dkaf143-B7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12879-019-4065-5","article-title":"Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study","volume":"19","author":"Keighley","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025070104562519300_dkaf143-B8","doi-asserted-by":"publisher","first-page":"myad132","DOI":"10.1093\/mmy\/myad132","article-title":"Pichia kudriavzevii (Candida krusei): a systematic review to inform the World Health Organisation priority list of fungal pathogens","volume":"62","author":"Nguyen","year":"2024","journal-title":"Med Mycol"},{"key":"2025070104562519300_dkaf143-B9","doi-asserted-by":"publisher","first-page":"myae042","DOI":"10.1093\/mmy\/myae042","article-title":"Candida auris\u2014a systematic review to inform the World Health Organization fungal priority pathogens list","volume":"62","author":"Kim","year":"2024","journal-title":"Med Mycol"},{"key":"2025070104562519300_dkaf143-B10","doi-asserted-by":"publisher","first-page":"myae041","DOI":"10.1093\/mmy\/myae041","article-title":"Candida glabrata (Nakaseomyces glabrata): a systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization fungal priority pathogens list","volume":"62","author":"Beardsley","year":"2024","journal-title":"Med Mycol"},{"key":"2025070104562519300_dkaf143-B11","author":"ClinicalTrials.gov"},{"key":"2025070104562519300_dkaf143-B12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2025070104562519300_dkaf143-B13","doi-asserted-by":"publisher","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B14","doi-asserted-by":"publisher","first-page":"e02154-17","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B15","doi-asserted-by":"publisher","first-page":"e01626-16","DOI":"10.1128\/AAC.01626-16","article-title":"Pharmacokinetics of the novel echinocandin CD101 in multiple animal species","volume":"61","author":"Ong","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B16","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025070104562519300_dkaf143-B17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2025070104562519300_dkaf143-B18","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1093\/jac\/dkac206","article-title":"Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient","volume":"77","author":"Pechacek","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025070104562519300_dkaf143-B19","doi-asserted-by":"publisher","first-page":"e00750-24","DOI":"10.1128\/aac.00750-24","article-title":"Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)","volume":"68","author":"Ponta","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5194\/jbji-9-213-2024","article-title":"Efficacy of rezafungin in a case of Candida spondylodiskitis","volume":"9","author":"Lahouati","year":"2024","journal-title":"J Bone Jt Infect"},{"key":"2025070104562519300_dkaf143-B21","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/microorganisms12050903","article-title":"Salvage therapy with rezafungin for Candida parapsilosis spondylodiscitis: a case report from expanded access program","volume":"12","author":"Viceconte","year":"2024","journal-title":"Microorganisms"},{"key":"2025070104562519300_dkaf143-B22","author":"Chiurlo"},{"key":"2025070104562519300_dkaf143-B23","doi-asserted-by":"publisher","first-page":"ofaf034","DOI":"10.1093\/ofid\/ofaf034","article-title":"Long-term safety and effectiveness of rezafungin treatment in candidemia and invasive candidiasis: results from an early access program in Italy and Germany","volume":"12","author":"Trapani","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025070104562519300_dkaf143-B24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40121-025-01120-7","article-title":"It\u2019s here, it\u2019s there, there\u2019s fungi everywhere: a case series utilizing rezafungin for invasive candidiasis","volume":"14","author":"Keck","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2025070104562519300_dkaf143-B25","doi-asserted-by":"publisher","first-page":"ofab431","DOI":"10.1093\/ofid\/ofab431","article-title":"Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: a case report","volume":"8","author":"Adeel","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025070104562519300_dkaf143-B26","doi-asserted-by":"publisher","first-page":"dlae042","DOI":"10.1093\/jacamr\/dlae042","article-title":"Treatment of Candida glabrata native valve endocarditis with rezafungin: a case report","volume":"6","author":"Mori","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2025070104562519300_dkaf143-B27","author":"Trapani"},{"key":"2025070104562519300_dkaf143-B28","doi-asserted-by":"publisher","first-page":"101545","DOI":"10.1016\/j.mycmed.2025.101545","article-title":"Disseminated infection with Candida dubliniensis after ravulizumab and treatment with rezafungin\u2014a case report","volume":"35","author":"L\u00f6tsch","year":"2025","journal-title":"Med Mycol"},{"key":"2025070104562519300_dkaf143-B29","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s10875-023-01519-2","article-title":"Successful rezafungin treatment of an azole-resistant chronic mucocutaneous candidiasis in a STAT-1 gain-of-function patient","volume":"43","author":"Melenotte","year":"2023","journal-title":"J Clin Immunol"},{"key":"2025070104562519300_dkaf143-B30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/thoraxjnl-2013-203988","article-title":"Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis","volume":"69","author":"Keir","year":"2014","journal-title":"Thorax"},{"key":"2025070104562519300_dkaf143-B31","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025070104562519300_dkaf143-B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1164\/rccm.202410-2045ST","article-title":"Treatment of invasive pulmonary aspergillosis and preventive and empirical therapy for invasive candidiasis in adult pulmonary and critical care patients. An official American Thoracic Society clinical practice guideline","volume":"211","author":"Epelbaum","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2025070104562519300_dkaf143-B33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025070104562519300_dkaf143-B34","author":"ClinicalTrials.gov"},{"key":"2025070104562519300_dkaf143-B35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/antibiotics9100700","article-title":"Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care","volume":"9","author":"Ajaka","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025070104562519300_dkaf143-B36","author":"emc pi portal"},{"key":"2025070104562519300_dkaf143-B37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin\u2014mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2025070104562519300_dkaf143-B38","doi-asserted-by":"publisher","first-page":"e01009-17","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B39","doi-asserted-by":"publisher","first-page":"e00758-17","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B40","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/jac\/dky153","article-title":"Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model","volume":"73","author":"Hager","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025070104562519300_dkaf143-B41","doi-asserted-by":"publisher","first-page":"7601","DOI":"10.1128\/AAC.04134-14","article-title":"Abdominal candidiasis is a hidden reservoir of echinocandin resistance","volume":"58","author":"Shields","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B42","doi-asserted-by":"publisher","first-page":"ofz262","DOI":"10.1093\/ofid\/ofz262","article-title":"Development of high-level echinocandin resistance in a patient with recurrent Candida auris candidemia secondary to chronic candiduria","volume":"6","author":"Biagi","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025070104562519300_dkaf143-B43","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/jac\/dkl022","article-title":"Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis","volume":"57","author":"Laverdi\u00e8re","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2025070104562519300_dkaf143-B44","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","author":"Beyda","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025070104562519300_dkaf143-B45","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1128\/AAC.01763-15","article-title":"Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study","volume":"60","author":"Jensen","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B46","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cid\/ciac341","article-title":"Emergence of dalbavancin, vancomycin, and daptomycin nonsusceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization","volume":"75","author":"Zhang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025070104562519300_dkaf143-B47","doi-asserted-by":"publisher","first-page":"e02438-19","DOI":"10.1128\/AAC.02438-19","article-title":"Rezafungin in vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST reference method","volume":"64","author":"Helleberg","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562519300_dkaf143-B48","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.jval.2023.09.599","article-title":"EE333 Cost-effectiveness of once-weekly rezafungin for the treatment of candidemia and invasive candidiasis in the UK","volume":"26","author":"Muszbek","year":"2023","journal-title":"Value Health"},{"key":"2025070104562519300_dkaf143-B49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(22)00872-6","article-title":"Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study","volume":"23","author":"Hoenigl","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/7\/1885\/63180418\/dkaf143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/7\/1885\/63180418\/dkaf143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:56:35Z","timestamp":1751345795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/7\/1885\/8131441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,5,14]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf143","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,14]]}}}